Allan Shaw’s Post

📣 Join us for our upcoming webinar: Unlocking the full potential of immunopeptidomics with the timsTOF Ultra 📅 October 29, 2024 11:00 am - 12:00 pm EDT, 4:00 - 5:00 pm CET Why to join this webinar: The timsTOF Ultra can lead to high quality immunopeptidomes from limited sample Extensive HLA databases can significantly speed up the T-Cell-Receptor therapy development process The time is ripe to bring immunopeptidomics into clinical routine https://lnkd.in/efUZwFye

INDUSTRY NEWS - CAR-T in autoimmunity My thoughts on the news 'Cartesian Therapeutics clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M' https://lnkd.in/eHtpW7T3 This is an exciting development that expands on tantalizing CAR-T data in autoimmunity first reported in lupus last year. Is autoimmunity the saving grace for the CAR-T field as multiple companies migrate from oncology? The competition will be no less fierce in autoimmunity where mAbs have made significant advances over the years and are truly off-the-shelf products, and cheaper as well. One key question concerns how many CAR-T products can the autoimmunity field accommodate, especially if they are all targeting B cell specific antigens. Perhaps the competitive landscape will be adjudicated by the relative durability of any response. Whereas the durability of mAb function is dictated by standard pharmacokinetics, the durability of CAR-T responses may be longer if they function as an immunomodulatory reset to the immune system. Time and data will tell. #Alloplex #celltherapies #CAR-T #oncologyresearch #cancerresearch

Today, we are sharing our CEOs thoughts on a recent exciting industry development

Today our lab discussed a fascinating study exploring the role of type III IFNs in gut tissue damage and repair. Published: https://lnkd.in/g_94g_xC Preprint: https://lnkd.in/gB4n-6JT As a team deeply invested in interferons—especially type III IFNs—I’m always intrigued by research uncovering unique, non-redundant roles for IFN lambdas. It’s been widely accepted that type I and type III IFNs share signaling pathways via the same JAKs and STATs. But mounting evidence is challenging this narrative, suggesting there’s more to the story. * https://lnkd.in/giQyqvvh * https://lnkd.in/gjZan5_b And where it gets even more exciting is that emerging data hints that these signaling pathways might not be as similar as we thought. * https://lnkd.in/gktVnu4F * https://lnkd.in/gh6aPrnt * https://lnkd.in/g5bJQpVW What additional insights will the next study bring? Could these findings pave the way for a new generation of type III IFN-focused therapeutics? I think there’s a lot of potential here! What are your thoughts? Feel free to share with myself or fellow lab members Zhijie Chen shima shabani Mukesh Kumar Venkatramani!

Operate freely with our robust offering of ~500 standard cell lines, licensed, well characterized, and annotated for your screening needs. What sets OmniScreen™ apart? ⬇️ ✅Unmatched Selection: Choose from 30+ cancer indications. ✅Versatile Design: Engage in 3D models, drug combination studies, extended incubation & more. ✅Holistic Solution: From composite biomarker analysis to in vivo follow up with our XenoSelect™ panel. ✅Real-time Insights: Access results promptly with our real-time readouts. Unlock a future where your lead therapeutic agents are the next big breakthrough in preclinical drug development! Register by June 13th ➡️https://hubs.la/Q02yF2fP0 #CancerResearch #CellLines #DrugDevelopment

RPT: Battles of the Alphas Breakthrough Therapy Designation is based on the results from phase 1 and the ongoing phase 2 clinical trials that assessed the safety and efficacy of AlphaMedixTM. In the phase 1 study, treatment was well-tolerated, with a response rate (ORR according to RECIST 1.1) of 62.5% for the GEP-NET patients who had never received PRRT with LutatheraTM, which is based on the beta-particle emitter Lutetium-177. In the phase 2 trial, the target response rate has already been achieved ahead of top-line data, expected in mid-2024.

🚨 New #DiabetesDialogue! 🚨 Hear from John Buse, MD, PhD, as he discusses why he says the 2-part CATALYST trial might be the "biggest thing that I have ever done in my career" with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES. Get a deep dive into the trial, including part 2, which will examine use of mifepristone (Korlym; Corcept Therapeutics) among patients who screened positive for hypercortisolism. https://lnkd.in/et4uQuDg #Type2Diabetes #Hypercortisolism

Day 2 of the Alcor Drug Discovery Platform! Join us for a compelling presentation by Jeff R. Swarz Ph.D., CEO of Ated Therapeutics, as he unveils groundbreaking advancements in Parkinson's Disease diagnostics. Discover how a rapid, accurate, blood-based tRNA diagnostic test is poised to revolutionize early detection and treatment strategies. Stay ahead of the curve in neurodegenerative research! #AlcorDrugDiscovery #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits 

"I think the future [of Alzheimer's care is] going to lay—just like in cancer—with #CombinationTherapy and #PrecisionMedicine driven by #biomarkers." - Howard Fillit, MD This morning, ADDF Co-Founder and Chief Science Officer, Dr. Fillit spoke with CNBC Squawk Box, comparing #AntiAmyloids, the first class disease-modifying Alzheimer's drugs, to the first class of #chemotherapy drugs, as well as discussing the future of #Alzheimers care, how the #BiologyOfAging plays a role, and more. Watch the full interview here: https://cnb.cx/4aWFI1R

If you are experiencing challenges of Liquid Biopsy Assay Validation, watch this insightful webinar from Krystyna Nahlik from LGC Clinical Diagnostics who shares her expertise on overcoming the unique challenges faced in the validation process and introduces the recent and upcoming additions to the #Seraseq liquid biopsy portfolio https://lnkd.in/e-QezaX3